Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Resources>Application Notes>This Application Note
  Application Notes
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Scroll Up
Scroll Down

Improved cell viability assay performance using PrestoBlue® Reagent
Bookmark and Share

Tecan Trading AG

Resazurin is a well-established fluorescent dye that is frequently used in various commercially available assay systems. It is a redox indicator that can be added directly to cells in culture. Viable cells convert the dark blue oxidized form of the dye (resazurin) into a red-fluorescent reduced form (resorufin; λEx = 570 nm; λEm = 590 nm). This system is specific for cell viability as non-viable cells rapidly lose metabolic capacity to reduce resazurin, and thus no fluorescent signal is detected. 

Life Technologies offers an enhanced version of the commonly available resazurin-based assays, the PrestoBlue® Cell Viability Reagent. This novel dye offers the same analytical properties (fluorescence excitation and emission wavelength) as common resazurin-based assays (eg. alamarBlue®), but is characterized by a significantly shorter incubation time (minimum 15 mins vs 1 hr), increasing experimental efficiency and performance. 

This application note describes the evaluation of Life Technologies’ PrestoBlue® Cell Viability Reagent using the Infinite M200 PRO and the Infinite M1000 PRO multimode microplate readers. 


Further Information


SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!